Public Meeting on Levothyroxine Sodium Equivalence
04/20/2005
Federal Register Notice: FDA is holding a public meeting 5/23 on the therapeutic equivalence of levothyroxine sodium drug products. The meeting will include FDA staff and representatives of the American Thyroid Association, the Endocrine Society, and the American Association of Clinical Endocrinologists. Participants will discuss FDA's regulatory standards and methodological approaches for determining therapeutic equivalence between levothyroxine sodium drug products. The agency is seeking comments and input from interested constituencies, including patient advocacy and education groups, and pharmaceutical sponsors. The meeting will be held from 8:30 a.m. to 5 p.m. at the National Transportation Safety Board Boardroom and Conference Center, 429 L'Enfant Plaza, SW., Washington, DC 20594. Contact Rose Cunningham, (301) 443-5595, To view this notice, click here.
